CTN001 / Centenaire Biosci - LARVOL DELTA

Centenaire, stomach cancer and breast cancer 'HER2 antibody' selected as KDDF project [Google translation] (Biospectator) - "Centenaire Biosciences announced on the 1st that its HER2 antibody 'CTN001' pipeline, which is being developed as a treatment for stomach cancer and breast cancer, was selected as a non-clinical development project for the 1st National New Drug Development Program (KDDF) in 2024...CTN001 is an antibody targeting HER2 and is a pipeline to which Centenaire's unique antibody engineering platform, Twin Fc-ICE (immune cell engager), is applied. The Twin Fc-ICE platform is a platform that optimizes antibody function by rearranging the antibody structure to increase the total binding avidity between cancer cells and immune cells expressing Fc receptors....'Based on KDDF’s support for CTN001, Centenaire is completing the non-clinical development of CTN001 as quickly as possible and proceeding with development with the goal of entering the clinical trial in early 2026.'"

Financing • New trial • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

CTN001, a first Twin Fc-immune cell engager, with a superior potency against Her2+ and Her2-low cancers by engaging multiple Fc-mediated mechanisms (AACR 2024) - "Consistently, CTN001 showed better anti-tumor efficacy than trastuzumab or its combination with pertuzumab in Her2+ tumor xenograft model and, surprisingly, even in Her2-low or resistant models. These results suggest that CTN001 can provide new therapeutic options for treating Her2-low patients differentiated from antibody-drug conjugates (ADCs), and that the Twin Fc-ICE can be an innovative platform to overcome limitations of existing therapeutics."

Immune cell • Oncology • HER-2

Twin Fc-immune cell engager (ICE): A novel antibody platform for cancer immunotherapy with enhanced avidity for Fcγ receptors and complement (AACR 2024) - "Indeed, flow cytometry analysis revealed that treatment of CTN001 alone results in higher Fc load on HER2-expressing cancer cells than combination of two anti-HER2 IgG1 mAbs, trastuzumab and pertuzumab. The serum half-life of CTN001 at 10 mg/kg intravenous dose in rats is found non-inferior to that of trastuzumab (~12 days versus ~7 days). Taken together, Twin Fc-ICE provides an optimized platform with drug-like properties, which leverages avidity effects of Fc to potentiate therapeutic efficacy of antibody."

Immune cell • Oncology